Composition, form of production and packaging
Lyophilizate for the preparation of a solution for the / m introduction in the form of powder or a porous mass of white or white with a yellowish hue.
extract of the prostate (in terms of water-soluble peptides) 5 mg
Excipients: glycine - 25 mg.
5 mg - ampoules of colorless glass (5) - packings, cell planimetric (1) - packs of cardboard.
5 mg - ampoules of colorless glass (5) - packages of cellular contour (2) - packs cardboard.
5 mg - ampoules of colorless glass (5) - packs of cardboard.
INSTRUCTION FOR THE SPECIALIST.
Description of the drug approved by the manufacturer for the printed edition of 2016.
An animal of animal origin. Has an organotropic effect on the prostate gland. Helps reduce edema, stagnation of secretion and leukocyte infiltration of the prostate.Normalizes the secretory function of epithelial cells. Has anti-inflammatory effect. Due to antiaggregant properties it prevents the development of venous thrombosis in the prostate gland.
Data on the pharmacokinetics of the drug are not available.
- chronic prostatitis;
- states after surgical interventions on the prostate gland.
The drug is administered in / m at 5-10 mg 1 time / day. Before the injection, the lyophilizate is dissolved in 1-2 ml of a 0.9% solution of sodium chloride, or 0.25-0.5% solution of novocaine, or water for injection. The duration of treatment is 5-10 days. If necessary, the course can be repeated after 1-6 months.
If one or several injections of the drug are missed, treatment is not stopped, an extension of the course of treatment for the number of missed days of use is recommended.
Allergic reactions: urticaria.
In case of allergic reactions should stop treatment, prescribe antihistamines.
- children and adolescence under 18;
- Hypersensitivity to the components of the drug.
PREGNANCY AND LACTATION
The drug is not prescribed to women.
APPLICATION FOR CHILDREN
Contraindicated in children under 18 years of age.
Features of the action at the first introduction and when it is withdrawn the drug does not.
The use of the drug in chronic diseases has no special features.
Impact on the ability to drive vehicles and manage mechanisms
The drug does not affect the ability to drive vehicles, work with moving mechanisms and engage in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions.
Cases of overdose of Prostatilen В® are not described.
Clinically significant effects of the interaction of Prostatilen В® with other drugs have not been identified.
TERMS OF RELEASE FROM PHARMACY
The drug is released by prescription.
TERMS AND CONDITIONS OF STORAGE
The drug should be stored out of the reach of children at a temperature of no higher than 20 В° C. Shelf life - 3 years.